Sinopharm Group Co. Ltd. will convene its 2025 AGM on 18 June 2026 in Shanghai, alongside separate H- and Domestic-share class meetings, to vote on a series of capital-management proposals.

Key items on the ballot include:

1. Board authorisation to provide guarantees for subsidiaries up to 30% of the company’s latest audited total assets within a rolling 12-month period. The mandate would run until the next AGM.

2. A general mandate allowing the Board to issue up to 20% of each share class in new equity or treasury-share disposals during the 12 months following approval. Based on the current share capital of 1,778.85 million Domestic Shares and 1,341.81 million H Shares, the ceiling equates to 355.77 million Domestic Shares and 268.36 million H Shares.

3. Authority to repurchase up to 10% of outstanding H Shares (excluding treasury shares) during the same period, translating to a maximum 134.18 million H Shares. Repurchased stock may be cancelled or held as treasury shares.

4. An application to extend the validity of the company’s RMB-denominated non-financial corporate debt financing instruments registration with the National Association of Financial Market Institutional Investors from two to three years, moving the expiry to 19 July 2027.

5. Re-appointment of Confucius International CPA Limited and Pan-China Certified Public Accountants LLP as international and domestic auditors, respectively, with 2026 fees estimated between RMB24.00 million and RMB27.50 million.

Shareholders on record as of 15 June 2026 are eligible to vote; the register closes from 15 to 18 June 2026. Proxies must be lodged no later than 24 hours before the respective meetings. Final-dividend entitlement will be determined on 30 June 2026, with payment expected by 18 August 2026.